HOME >> BIOLOGY >> NEWS
Other highlights in the July 7 JNCI

Study Evaluates Design of Phase I Trials for Targeted Cancer Drugs

One purpose of a phase I clinical trial of a new cytotoxic drug is to determine the side effects associated with increasing drug dose, i.e., determine the dose that produces the maximum effect at which the toxicity can still be tolerated. New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase inhibitors, pose challenges to this paradigm because they can achieve their maximum effect at levels lower than the maximum tolerated dose.

In a new study, Wendy R. Parulekar, M.D., and Elizabeth A. Eisenhauer, M.D., of Queen's University in Kingston, Ontario, reviewed endpoints used in 60 published phase I studies of targeted, non-cytotoxic anticancer agents. They found that the majority of studies used the traditional endpoint of toxicity to determine the recommended dose for the phase II trials. Nontraditional endpoints, such as measures of molecular drug effects in tumor or surrogate tissue or functional imaging studies, were not routinely incorporated into the study design and rarely formed the primary basis for dose selection.

The authors conclude that although phase I studies of targeted anticancer agents in general continue to use traditional endpoints for selection of the recommended phase II dose, suitable molecular measures of drug effect and the means to incorporate them in the early drug development process are needed to optimize dose selection and drug development strategies.

In an editorial, Edward L. Korn, Ph.D., of the National Cancer Institute, discusses the assumptions and considerations required for choosing an endpoint in a phase I trial of a cytotoxic agent, and the challenges in using nontraditional endpoints for the dose selection of targeted, non-cytotoxic agents.

Contact: Wendy Parulekar, Queen's University, wparulekar@ctg.queensu.ca


Possible T
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
6-Jul-2004


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the June 16 JNCI
5. Other Highlights in the June 2 JNCI
6. Other highlights in the May 19 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/12/2019)... ... 12, 2019 , ... Atlantic Ultraviolet Corporation (AUV), the premier ... voted their patented automatic and manual wipers the #1 best feature of the ... maintenance task required of an ultraviolet water purifier is quartz sleeve cleaning. A ...
(Date:11/6/2019)... ... November 06, 2019 , ... NDA Partners Chairman ... pharmaceutical industry executive with expertise in clinical pharmacology and pharmacometrics and a widely ... data analytics, has joined the firm as an Expert Consultant. , Dr. Stanski ...
(Date:11/2/2019)... (PRWEB) , ... October 31, 2019 , ... In this ... with a successful career in research and consulting. , The Beyond the Lab Podcast ... episodes feature interviews from alumni who have jobs in the biomedical field — and ...
Breaking Biology News(10 mins):
(Date:11/12/2019)... ... November 12, 2019 , ... ... announced that Immatics Biotechnologies , a clinical-stage biopharmaceutical company developing T-cell ... their R&D operations related to the discovery and development of high-affinity and ...
(Date:11/6/2019)... ... November 06, 2019 , ... Diversified Technologies, Inc. ... of fruits and vegetables per hour to improve processing. , The DTI Industrial PEF ... tons per hour to increase juice yields by up to 50% and achieve up ...
(Date:11/2/2019)... ... October 31, 2019 , ... ... used to communicating with each other: study managers, principal investigators, supply chain managers, ... a party is not informed of the latest data, potentially leading to patient ...
(Date:10/29/2019)... ... October 28, 2019 , ... CaroGen Corporation , ... , Professor Jack R Wands, MD, of Brown University , ... , Professor Gil Mor, MD, PhD, of Wayne State University, formerly a ...
Breaking Biology Technology:
Cached News: